Tobacco Use Disorder: Clinical Trials

204 trials for Tobacco Use Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

154 completed, 18 terminated, 12 recruiting, 9 withdrawn. 204 Phase 2, 27 Phase 1, 25 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2204Completed 154, Terminated 18, Recruiting 12, Withdrawn 9, Unknown 8, Not yet recruiting 2, Active not recruiting 1
Phase 127Completed 20, Terminated 3, Withdrawn 3, Recruiting 1
Phase 325Completed 17, Unknown 4, Terminated 3, Recruiting 1

Follow Tobacco Use Disorder: new trials by email Literature Review of Tobacco Use Disorder trials Research Report on Tobacco Use Disorder

Trials (filtered) newest first · largest first

All 204 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Psilocybin on Craving in Nicotine Dependence
Psilocybin (drug) - Nicotine Dependence
Phase 2Not yet recruitingUniversity of British Columbia32027-01-012026-10-01
THCV Treatment for Smokers
Δ9-Tetrahydrocannabivarin (oral gummy), Matched Placebo (oral gummy) - Tobacco Use Disorder, Smoking Cessation
Phase 2Not yet recruitingUniversity of California, Los Angeles322026-10-012026-08-04
A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation
Non-invasive vagus nerve stimulator plus nicotine replacement patches, nicotine replacement patches - Smoking Cessation
Phase 2 / Phase 3RecruitingMayo Clinic1502026-06-042026-09-25
Accelerated dTMS Smoking Cessation
Bilateral deep accelerated repetitive transcranial magnetic stimulation - Tobacco Use Disorder, Addiction Nicotine
Phase 2RecruitingWaypoint Centre for Mental Health Care402026-02-242026-04-21
The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction
VapeAway filter system - Addiction Nicotine
Phase 2RecruitingVapeAway702025-12-242026-01-07
A Trial of Varenicline for E-cigarette Cessation
Varenicline 1mg BID, Placebo - E-cigarette Use, Vaping
Phase 2RecruitingYale University3262025-10-142025-12-17
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
Varenicline - Alcohol Use Disorder, Hiv
Phase 2TerminatedYale University32025-06-162026-11-06
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
Cytisinicline, Placebo Oral Capsule - Smoking Cessation, Tobacco Use Disorder
Phase 2RecruitingUniversity of California, Los Angeles642024-12-052025-12-03
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
Varying the nicotine content of cigarettes, Varying the nicotine content of e-cigarettes - Tobacco Use Disorder
Phase 2RecruitingUniversity of Vermont3082024-11-012025-06-27
Cannabidiol for Reducing Cigarette Use
Cannabidiol (CBD) 800 mg, Placebo - Tobacco Use Disorder, Tobacco Smoking
Phase 2RecruitingUniversity of California, Los Angeles1202024-10-312026-04-13
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
Placebo, AB-free kava - Smoking
Phase 2RecruitingUniversity of Florida762024-06-062026-01-27
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Psilocybin, Niacin - Tobacco Use Disorder
Phase 2RecruitingJohns Hopkins University662023-11-012026-06-29
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
active repetitive transcranial magnetic stimulation, sham repetitive transcranial magnetic stimulation, cognitive behavioral therapy for smoking cessation - Tobacco Use Disorder
Phase 2RecruitingVA Office of Research and Development502023-10-312026-02-18
Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans
Varenicline, Placebo - Tobacco Use Disorder, Cannabis Use Disorder
Phase 2WithdrawnVA Office of Research and Development2023-04-172024-08-27
Overcoming Nicotine Dependence to Enable Quitting
Nicotine Replacement Therapy (NRT) Sampling, Practice Quitting (PQ) Counseling, Motivational Interviewing (MI) Counseling - Tobacco Use, Smoking Cessation
Phase 1 / Phase 2RecruitingRush University Medical Center7802023-03-242026-09-09
Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO)
NFL-101, Placebo - Smoking Cessation, Nicotine Dependence
Phase 2CompletedNFL Biosciences SAS342023-02-212023-10-19
Effects of Semaglutide on Nicotine Intake
Semaglutide, Sham/placebo - Tobacco Use Disorder, Nicotine Addiction
Phase 2CompletedUniversity of North Carolina, Chapel Hill242022-10-072025-08-22
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
Contingency Management, Non-contingent control - Alcohol Use Disorder (AUD), Nicotine Use Disorder
Phase 2RecruitingWashington State University2052022-07-112026-07-06
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
Kava, Placebo - Smoking
Phase 2TerminatedUniversity of Florida192022-06-092026-09-03
Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties
Coaching calls, Nicotine replacement therapy, Financial Incentives - Cigarette Smoking, Nicotine Dependence
Phase 2CompletedUniversity of Oklahoma1652022-03-092024-12-30

Showing 20 of 204. Sign in to see all of them.

Narrower conditions

Smoking Cessation (56)  ·  Smoking (46)  ·  Cigarette Smoking (18)  ·  Alcoholism (12)  ·  Tobacco Use (10)  ·  Tobacco Use Cessation (10)  ·  Vaping (10)  ·  Carcinoma, Non-Small-Cell Lung (7)  ·  Lung Neoplasms (7)  ·  Schizophrenia (7)  ·  Body Weight (4)  ·  Small Cell Lung Carcinoma (4)  ·  Behavior, Addictive (3)  ·  Harm Reduction (3)

Broader conditions

Chemically-Induced Disorders (204)  ·  Mental Disorders (204)  ·  Substance-Related Disorders (201)  ·  Behavior (118)  ·  Health Behavior (65)  ·  Smoking (28)  ·  Tobacco Use (21)  ·  Tobacco Smoking (18)  ·  Alcohol-Related Disorders (10)  ·  Lung Diseases (10)  ·  Respiratory Tract Diseases (10)  ·  Neoplasms (9)  ·  Neoplasms by Site (9)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Respiratory Tract Neoplasms (9)

Interventions

Tobacco Use Cessation Devices (31)  ·  Varenicline (27)  ·  Bupropion (18)  ·  Nicotine (17)  ·  Nicotine Replacement Therapy (10)  ·  Behavior Therapy (9)  ·  Sugars (9)  ·  Nicotine Chewing Gum (7)  ·  Electronic Nicotine Delivery Systems (6)  ·  Naltrexone (6)  ·  Acetylcysteine (4)  ·  Cognitive Behavioral Therapy (4)  ·  Counseling (4)  ·  Tobacco Products (4)  ·  Aspirin (3)

Sponsors

National Institute on Drug Abuse (NIDA) (27)  ·  Yale University (14)  ·  University of Pennsylvania (13)  ·  Brown University (11)  ·  Mayo Clinic (11)  ·  University of Vermont (10)  ·  Duke University (8)  ·  University of Minnesota (8)  ·  Centre for Addiction and Mental Health (7)  ·  Medical University of South Carolina (7)  ·  National Cancer Institute (NCI) (6)  ·  University of California, Los Angeles (4)  ·  VA Office of Research and Development (4)  ·  Johns Hopkins University (3)  ·  University of Florida (3)

Countries

United States (177)  ·  Canada (10)  ·  France (3)  ·  Denmark (2)  ·  Australia (1)  ·  Germany (1)  ·  India (1)  ·  Italy (1)  ·  South Africa (1)  ·  Sweden (1)

Top investigators

Dorothy Hatsukami, Ph.D. (9)  ·  Jed E Rose, Ph.D. (6)  ·  Dorothy Hatsukami, PhD (5)  ·  Jennifer Tidey, Ph.D. (4)  ·  Jennifer W. Tidey (3)  ·  Rebecca Ashare, Ph.D. (3)  ·  Bernard Le Foll, MD, PhD (2)  ·  Caryn Lerman, Ph.D. (2)  ·  Caryn Lerman, PhD (2)  ·  Eric T. Moolchan, M.D. (2)  ·  James M Davis, M.D. (2)  ·  Jed E. Rose, Ph.D. (2)  ·  John R Hughes, MD (2)  ·  John R. Knight, MD (2)  ·  Jon O Ebbert, MD (2)

Results publications

PMID 37230961, PMID 37142273, PMID 42560883, PMID 32628945, PMID 33079196, PMID 34242666, PMID 34255068, PMID 36208817, PMID 38236223, PMID 25192771, PMID 33605440, PMID 39240566, PMID 16960700, PMID 17587504, PMID 18096137, PMID 18381502, PMID 18827129, PMID 18837602, PMID 19339135, PMID 20056957, PMID 20078491, PMID 20542391, PMID 20590478, PMID 20707784, PMID 20934835, PMID 20947286, PMID 21221531, PMID 21276244, PMID 21475970, PMID 21652735, PMID 21762878, PMID 21846661, PMID 22007015, PMID 22097928, PMID 22160487, PMID 22197799, PMID 22218402, PMID 22352784, PMID 22452559, PMID 22464727, PMID 22993168, PMID 23024246, PMID 23261228, PMID 23429725, PMID 23454876, PMID 23460656, PMID 23536105, PMID 23586456, PMID 23603206, PMID 23873976

NIH funding

P50DA027840 (6), P50AA015632 (4), P50DA036114 (3), U54DA036114 (3), K01DA019446 (2), N01CN00031 (2), P01CA096964 (2), P30CA023074 (2), P50DA013333 (2), U01DA019378 (2), 1RC1DA028279-01 (1), 2005 (1), I01CX002357 (1), K01MD015295 (1), K23DA019950 (1)